









Markets
/
Stocks
/
nasdaq-dawn
/

Day One Biopharmaceuticals Inc

DAWN

11.410USD

+0.930+8.87%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.17BMarket Cap

LossP/E TTM



Day One Biopharmaceuticals Inc

11.410

+0.930+8.87%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Day One Biopharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Day One Biopharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 42 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Day One Biopharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

42 / 392

Overall Ranking

148 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Day One Biopharmaceuticals Inc Highlights

StrengthsRisks

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

Fairly Valued

The company’s latest PE is -7.46, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 86.52M shares, increasing 0.09% quarter-over-quarter.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 2.91K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.76.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

22.667

Target Price

+116.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Day One Biopharmaceuticals Inc is 7.23, ranking 138 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 39.80M, representing a year-over-year decrease of 57.56%, while its net profit experienced a year-over-year decrease of 153.26%.

Score

Industry at a Glance

Previous score

7.23

Change



Financials

6.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.39

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Day One Biopharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Day One Biopharmaceuticals Inc is 7.27, ranking 142 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.46, which is -43.49% below the recent high of -4.22 and -126.81% above the recent low of -16.93.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 42/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Day One Biopharmaceuticals Inc is 8.20, ranking 154 out of 392 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 29.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.20

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

22.667

Target Price

+111.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Day One Biopharmaceuticals Inc

DAWN

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Day One Biopharmaceuticals Inc is 7.40, ranking 75 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.43 and the support level at 9.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.06

Change

0.34

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.316

Neutral

RSI(14)

55.668

Neutral

STOCH(KDJ)(9,3,3)

31.246

Buy

ATR(14)

0.957

Low Volatility

CCI(14)

-51.101

Neutral

Williams %R

53.274

Neutral

TRIX(12,20)

0.744

Sell

StochRSI(14)

82.072

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

11.058

Buy

MA10

11.375

Buy

MA20

11.224

Buy

MA50

9.845

Buy

MA100

8.801

Buy

MA200

7.815

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Day One Biopharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 115.65%, representing a quarter-over-quarter decrease of 3.49%. The largest institutional shareholder is The Vanguard, holding a total of 6.27M shares, representing 6.11% of shares outstanding, with 4.37% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Access Industries, Inc.

12.93M

Fidelity Management & Research Company LLC

7.61M

-17.27%

Atlas Venture

6.43M

BlackRock Institutional Trust Company, N.A.

6.43M

-5.43%

The Vanguard Group, Inc.

Star Investors

6.17M

+0.08%

Deerfield Management Company, L.P.

4.71M

+26.38%

Franklin Advisers, Inc.

3.45M

-14.83%

Rubric Capital Management LP

3.38M

State Street Investment Management (US)

3.24M

+20.48%

Pictet Asset Management Ltd.

2.37M

-36.25%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Day One Biopharmaceuticals Inc is 4.22, ranking 98 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -1.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.